Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review
Vicente F Corrales-Medina1, Daniel M Musher
1Division of Infectious Diseases, Department of Medicine, University of Ottawa, Ontario, Canada. vcorrales@toh.on.ca
Abstract:
Despite the availability of excellent antibiotics, the mortality from community-acquired pneumonia (CAP) remains substantial. Most deaths occur during the first week of hospitalization. Because antibiotics rapidly eradicate bacteria from pulmonary secretions, an ongoing inflammatory response may be responsible for the poor outcome, and treatment with immunomodulatory drugs might be beneficial in this setting. Macrolides and statins exert a broad range of anti-inflammatory effects. Although randomized control trials have not been done, clinical evidence favors the addition of a macrolide to a beta-lactam for the treatment of pneumococcal pneumonia and supports a role for macrolides in the treatment of all-cause CAP without regard to their anti-microbial activity. The weight of several retrospective studies suggests that statins be considered in treating acute CAP. Further support for the use of statins derives from the high association between pneumonia and acute myocardial infarction. Aspirin might also be of benefit in treating patients hospitalized for pneumonia because of its anti-inflammatory activity as well as its benefits in acute myocardial infarction. Treatment of CAP with corticosteroids has yielded mixed results and the value of this approach is not well established, although further research is currently underway. Ibuprofen is not of benefit in treating sepsis in humans and glitazones may increase the risk of severe pneumonia.
Insights
Community-acquired pneumonia (CAP) mortality persists despite antibiotics. Immunomodulatory drugs like macrolides and statins may improve outcomes by reducing inflammation, warranting further investigation for CAP treatment.
Area of Science:
- Pulmonology
- Pharmacology
- Immunology
Background:
- Community-acquired pneumonia (CAP) continues to have substantial mortality, particularly within the first week of hospitalization.
- Antibiotics effectively clear bacteria but may not fully address the persistent inflammatory response contributing to poor outcomes in CAP.
- Exploring immunomodulatory agents alongside antibiotics is a promising avenue for improving CAP treatment efficacy.
Purpose of the Study:
- To review the potential benefits of immunomodulatory drugs in treating community-acquired pneumonia.
- To evaluate the role of macrolides, statins, and aspirin in managing CAP, considering their anti-inflammatory properties.
- To assess the current evidence for adjunctive therapies in CAP treatment beyond standard antibiotic regimens.
Main Methods:
- Literature review of clinical evidence and retrospective studies on immunomodulatory drugs in CAP.
- Analysis of anti-inflammatory effects of macrolides and statins.
- Examination of associations between pneumonia, cardiovascular events, and potential therapeutic agents.
Main Results:
- Clinical evidence suggests adding macrolides to beta-lactams for pneumococcal pneumonia and potentially for all-cause CAP, irrespective of antimicrobial activity.
- Retrospective studies indicate that statins may be beneficial in acute CAP treatment, supported by their association with reduced cardiovascular events.
- Aspirin's anti-inflammatory properties may offer benefits in hospitalized pneumonia patients, particularly those with concurrent acute myocardial infarction.
Conclusions:
- Macrolides and statins show potential as adjunctive therapies for community-acquired pneumonia due to their anti-inflammatory effects.
- Further research, including randomized controlled trials, is needed to establish the definitive role of these immunomodulatory agents in CAP management.
- While corticosteroids have shown mixed results, and ibuprofen and glitazones are not recommended, macrolides, statins, and aspirin warrant consideration in CAP treatment strategies.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia II: Pathophysiology
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...